Search - tctmd.com

Displaying 361 - 380 of 584

Sort: Relevancy | Date

Presentation TCT 2014

Reversal of Factor Xa Inhibition

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Lisa K. Jennings

September 15, 2014

Presentation TCT 2014

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Michael D. Ezekowitz

September 15, 2014

Presentation TCT 2014

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Christopher B. Granger

September 15, 2014

Presentation TCT 2014

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson

September 15, 2014

Presentation TCT 2014

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Laura Mauri

September 15, 2014

Presentation TCT 2014

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Jonathan L. Halperin

September 15, 2014

Presentation TCT 2014

The REG1 Anticoagulation System: Factor IX Inhibitor Using RNA Aptamer Technology

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, A. Michael Lincoff

September 15, 2014

Presentation TCT 2014

The Triple Therapy Conundrum: Treatment of the PCI Patient with Atrial Fibrillation

Presenter: Matthew J. Price, C. Michael Gibson

September 15, 2014

News Daily News

Según los Datos Angiográficos, Acuerdo Solo Moderado entre las Lecturas del NCDR y del Laboratorio Central

Yael L. Maxwell

February 12, 2014

News Daily News

For Angiographic Data, Only Moderate Agreement Between NCDR, Core Lab Readings

Yael L. Maxwell

February 12, 2014

Presentation TCT 2013

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Presenter: C. Michael Gibson

October 31, 2013

Presentation

Pharmacology in High-Risk PCI: Focus on Clinical Outcomes

Presenter: C. Michael Gibson

October 31, 2013

Presentation TCT 2013

Acute Coronary Syndrome and Atrial Fibrillation: 1 + 1 = 5

Presenter: C. Michael Gibson

October 29, 2013

Presentation Scripps 2013

The Challenges of Triple Therapy: Managing the DES Patient Who Also Requires Anti-coagulation

Presenter: C. Michael Gibson

October 03, 2013

News Industry News

Atrium Medical announces 1-year results of the INFUSE-AMI trial

May 03, 2013

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Caitlin E. Cox

April 19, 2013

Presentation

Reduction of Stent Thrombosis in ACS Patients Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51

Presenter: C. Michael Gibson

April 17, 2013

Presentation PCI Outcomes 2013

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Presenter: C. Michael Gibson

March 07, 2013

Presentation TCT 2013

Simple Measures of ST-Segment Resolution Predict Infarct Size: The INFUSE-AMI Trial

Presenter: Joe Dizon, Sorin Brener, Akiko Maehara, Bernhard Witzenbichler, Jacek Godlewski, Helen Parise, Jan-Henk Dambrink, Roxana Mehran, C. Michael Gibson, Gregg Stone

January 31, 2013

Advertisement

Reversal of Factor Xa Inhibition

Edoxaban in ACS and Atrial Fibrillation: Risk/Benefit Analysis and Future Directions

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits

The REG1 Anticoagulation System: Factor IX Inhibitor Using RNA Aptamer Technology

The Triple Therapy Conundrum: Treatment of the PCI Patient with Atrial Fibrillation

Según los Datos Angiográficos, Acuerdo Solo Moderado entre las Lecturas del NCDR y del Laboratorio Central

For Angiographic Data, Only Moderate Agreement Between NCDR, Core Lab Readings

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Pharmacology in High-Risk PCI: Focus on Clinical Outcomes

Acute Coronary Syndrome and Atrial Fibrillation: 1 + 1 = 5

The Challenges of Triple Therapy: Managing the DES Patient Who Also Requires Anti-coagulation

Atrium Medical announces 1-year results of the INFUSE-AMI trial

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Reduction of Stent Thrombosis in ACS Patients Treated with Rivaroxaban in ATLAS ACS 2-TIMI 51

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Simple Measures of ST-Segment Resolution Predict Infarct Size: The INFUSE-AMI Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content